Brain monoamine oxidase activity after in vivo-chronic iprindole treatment.
The effects of chronic administration of three different doses of iprindole on the monoamine oxidase activity and neurotransmitter content were studied in the cerebral cortex, the mesencephalon and the cerebellum of mouse brain. The treatment inhibited mitochondrial monoamine oxidase activity of all three brain regions studied, although a dose-response inhibitory effect was found only in the mesencephalon. Brain regional serotonin contents were markedly increased after iprindole treatment. The 5-hydroxyindoleacetic acid contents showed a significant decrease only in the cerebral cortex. Neither dopamine nor norepinephrine brain regional contents were significantly altered. On the basis of these results it is suggested that a substrate-specific inhibition of monoamine oxidase is involved in the mechanism of action of this tricyclic antidepressant.
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D002531:Cerebellum / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007211:Indoles / Q000494:pharmacology*; D007488:Iprindole / Q000494:pharmacology*; D008297:Male; D008636:Mesencephalon / Q000187:drug effects; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology; D008995:Monoamine Oxidase / Q000378:metabolism*; D009115:Muridae; D009638:Norepinephrine / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism
D007211:Indoles; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D007488:Iprindole; D008995:Monoamine Oxidase; D004298:Dopamine; D009638:Norepinephrine